IP Library Granted Patent US 8,097,243
Granted Patent B2
US 8,097,243 · App. 12/755,266 · Granted Jan 17, 2012

Microparticle-based transfection and activation of dendritic cells

Assignee: Novartis Vaccines and Diagnostics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,097,243
App. No.
12/755,266
Granted
Jan 17, 2012
Kind
B2
Abstract

The present invention provides an effective method for the transfection of dendritic cells by non-viral methods. The present invention provides this benefit by incubating dendritic cells and a specified transfection agent. The transfection agent comprises a polynucleotide and microparticles, with the microparticles being comprised of biodegradable polymer and cationic detergent. The dendritic cells and transfection agent are incubated for a time sufficient to transfect the dendritic cells with the polynucleotide.

Claims (7)

1. A method for producing an immune response in a vertebrate subject in need thereof comprising:

activating T cells by subjecting them to dendritic cells produced by a method that comprises incubating the dendritic cells and a transfection agent for a time sufficient to transfect the dendritic cells with the polynucleotide, said transfection agent comprising a polynucleotide that encodes an antigen associated with a virus or a tumor adsorbed on microparticles comprised of a biodegradable polymer and a cationic detergent, wherein polynucleotide is not entrapped within said microparticles;

administering said activated T cells to said subject.

2. The method according to claim 1 , in which the dendritic cells and T cells originate from the vertebrate subject.

3. The method according to claim 1 , in which the dendritic cells and T cells originate from a healthy vertebrate subject MHC-matched to the vertebrate subject.

4. The method according to claim 1 , in which the T cells are administered parenterally.

5. The method according to claim 1 , in which the T cells are administered by direct injection into affected tissue.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2011
From: DONNELLY, JOHN J.; DENIS-MIZE, KIMBERLY S.; OTT, GARY S.
To: CHIRON CORPORATION
Reel/Frame 025621/0664 →
CHANGE OF NAME Recorded Jan 11, 2011
From: CHIRON CORPORATION
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 025621/0723 →
Continuity (4)
Division 09715902 · Nov 17, 2000
Provisional Application 60166514 · Nov 19, 1999
Provisional Application 60146391 · Jul 29, 1999
Related Publication 20100196339A1 · Aug 5, 2010